IMNN Quote, Financials, Valuation and Earnings

Bio-Path Holdings has a net margin of -- compared to Imunon's net margin of --. Imunon's return on equity of -- beat Bio-Path Holdings's return on equity of --.

Imunon has a consensus price target of $10.25, signalling upside risk potential of 1977.84%. On the other hand Bio-Path Holdings has an analysts' consensus of $2.00 which suggests that it could grow by 1173.89%. Given that Imunon has higher upside potential than Bio-Path Holdings, analysts believe Imunon is more attractive than Bio-Path Holdings.

Imunon has a beta of 1.927, which suggesting that the stock is 92.726% more volatile than S&P 500. In comparison Bio-Path Holdings has a beta of -0.032, suggesting its less volatile than the S&P 500 by 103.201%.

Imunon has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bio-Path Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Imunon pays -- of its earnings as a dividend. Bio-Path Holdings pays out -- of its earnings as a dividend.

Imunon quarterly revenues are --, which are smaller than Bio-Path Holdings quarterly revenues of --. Imunon's net income of -$4.1M is lower than Bio-Path Holdings's net income of -$2.9M. Notably, Imunon's price-to-earnings ratio is -- while Bio-Path Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Imunon is 13.05x versus -- for Bio-Path Holdings. Usually stocks with elevated PS ratios are considered overvalued.

MetaVia has a net margin of -- compared to Imunon's net margin of --. Imunon's return on equity of -- beat MetaVia's return on equity of --.

Imunon has a consensus price target of $10.25, signalling upside risk potential of 1977.84%. On the other hand MetaVia has an analysts' consensus of $14.33 which suggests that it could grow by 2027.55%. Given that MetaVia has higher upside potential than Imunon, analysts believe MetaVia is more attractive than Imunon.

Imunon has a beta of 1.927, which suggesting that the stock is 92.726% more volatile than S&P 500. In comparison MetaVia has a beta of 0.214, suggesting its less volatile than the S&P 500 by 78.621%.

Imunon has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MetaVia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Imunon pays -- of its earnings as a dividend. MetaVia pays out -- of its earnings as a dividend.

Imunon quarterly revenues are --, which are smaller than MetaVia quarterly revenues of --. Imunon's net income of -$4.1M is lower than MetaVia's net income of -$3.7M. Notably, Imunon's price-to-earnings ratio is -- while MetaVia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Imunon is 13.05x versus -- for MetaVia. Usually stocks with elevated PS ratios are considered overvalued.

Nika Pharmaceuticals has a net margin of -- compared to Imunon's net margin of -35128.21%. Imunon's return on equity of -- beat Nika Pharmaceuticals's return on equity of --.

Imunon has a consensus price target of $10.25, signalling upside risk potential of 1977.84%. On the other hand Nika Pharmaceuticals has an analysts' consensus of -- which suggests that it could fall by --. Given that Imunon has higher upside potential than Nika Pharmaceuticals, analysts believe Imunon is more attractive than Nika Pharmaceuticals.

Imunon has a beta of 1.927, which suggesting that the stock is 92.726% more volatile than S&P 500. In comparison Nika Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Imunon has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nika Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Imunon pays -- of its earnings as a dividend. Nika Pharmaceuticals pays out -- of its earnings as a dividend.

Imunon quarterly revenues are --, which are smaller than Nika Pharmaceuticals quarterly revenues of $160. Imunon's net income of -$4.1M is lower than Nika Pharmaceuticals's net income of -$13K. Notably, Imunon's price-to-earnings ratio is -- while Nika Pharmaceuticals's PE ratio is 34,500.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Imunon is 13.05x versus -- for Nika Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Tivic Health Systems has a net margin of -- compared to Imunon's net margin of -2145.71%. Imunon's return on equity of -- beat Tivic Health Systems's return on equity of -192.41%.

Imunon has a consensus price target of $10.25, signalling upside risk potential of 1977.84%. On the other hand Tivic Health Systems has an analysts' consensus of -- which suggests that it could fall by --. Given that Imunon has higher upside potential than Tivic Health Systems, analysts believe Imunon is more attractive than Tivic Health Systems.

Imunon has a beta of 1.927, which suggesting that the stock is 92.726% more volatile than S&P 500. In comparison Tivic Health Systems has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Imunon has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tivic Health Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Imunon pays -- of its earnings as a dividend. Tivic Health Systems pays out -- of its earnings as a dividend.

Imunon quarterly revenues are --, which are smaller than Tivic Health Systems quarterly revenues of $70K. Imunon's net income of -$4.1M is lower than Tivic Health Systems's net income of -$1.5M. Notably, Imunon's price-to-earnings ratio is -- while Tivic Health Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Imunon is 13.05x versus 3.35x for Tivic Health Systems. Usually stocks with elevated PS ratios are considered overvalued.